We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Application form for companies and organisations to be a primary participant in the Community Emissions Trading Scheme.
How to complete and submit an Other Interest (OI) return using the HMRC spreadsheet or electronic flat text file.
Guidance on labelling for medicinal products used in clinical trials.
How investigators and sponsors should manage clinical trials during COVID-19
The following guidance has been jointly developed by the Heath Research Authority (HRA) and MHRA, in consultation with the Information Commissioners Office (ICO), on behalf of the UK.
How to use a quasi-experimental study to evaluate your digital health product.
Guidance on the collection, verification, and reporting of safety events in clinical trials of an investigational medicinal product.
What you need to know about being part of the Taking Part survey.
How to use a factorial randomised controlled trial to evaluate your digital health product.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab and requires JavaScript).